24 participants
Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2022-08-12
- Start Date:
- 2022-02-04
- Completion:
- 2025-01-31
Conditions
- Esophageal Squamous Cell Carcinoma
- HER-2 Protein Overexpression
- HER-2 Gene Amplification
Interventions
- DRUG
No Results Yet